Mannitol Injection 25%, USP (0.25 g/mL; 12.5 g/50 mL) is a sterile, nonpyrogenic osmotic diuretic solution for intravenous use, manufactured by Hospira, Inc. Available in a single-dose fliptop vial containing no bacteriostat or antimicrobial agent, it is indicated for the reduction of intracranial pressure, treatment of cerebral edema, and reduction of elevated intraocular pressure in both adult and pediatric patients.
Key Benefits
- FDA-Approved Dual Indication: Indicated for reduction of intracranial pressure and cerebral edema, as well as reduction of elevated intraocular pressure.
- Osmotic Diuretic Mechanism: Induces movement of intracellular water to extracellular and vascular spaces, producing clinically relevant pressure reduction.
- Adult and Pediatric Use: Approved for both adult and pediatric populations for intracranial and intraocular pressure indications.
- Preservative-Free Formulation: Single-dose vial contains no bacteriostat or antimicrobial agent, supporting safe clinical administration.
- High-Concentration Ready-to-Use Vial: Supplied as a 25% solution in a single-dose fliptop vial for streamlined intravenous administration.
Dosage and Administration
Mannitol Injection 25%, USP is for intravenous use only. Renal, cardiac, and pulmonary status should be evaluated prior to administration. Preferably administered through a central venous catheter.
- Intracranial Pressure / Cerebral Edema: 0.25 g/kg IV infusion over at least 30 minutes, repeated every 6 to 8 hours as needed.
- Intraocular Pressure Reduction: 1.5 to 2 g/kg as a single IV infusion over at least 30 minutes; when used preoperatively, administer 60 to 90 minutes before surgery.
Why Choose Mannitol Injection 25%, USP?
Mannitol Injection 25%, USP is a high-concentration osmotic diuretic specifically formulated for intravenous administration in a ready-to-use single-dose vial, addressing both intracranial and intraocular pressure indications as described in the prescribing information. Its preservative-free, single-dose design supports safe use in critical care and surgical settings where precise pressure management is required.
Warnings
- Hypersensitivity Reactions: Serious reactions including anaphylaxis, hypotension, dyspnea, cardiac arrest, and death have been reported; discontinue infusion immediately if signs or symptoms develop.
- Renal Complications: Irreversible renal failure has been reported; patients with pre-existing renal disease or receiving nephrotoxic drugs are at increased risk — discontinue if renal function worsens.
- CNS Toxicity: Confusion, lethargy, and coma (some fatal) have been reported, particularly with impaired renal function; discontinue Mannitol Injection if CNS toxicity develops.
Disclaimer: This product description was generated by AI and is intended for informational purposes only. Please consult the latest package insert.
